Startseite
Märkte
Charts & Ideen
Algo
Nachrichten
Store
Broker
Herunterladen
Wirtschaftskalender
Handelssignale
WebTerminal
Geben Sie
/
ein, um zu suchen: @user, $symbol
Suche
Einloggen
Eröffnen Sie ein Konto
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
VSTM
#2683
Verastem, Inc.
5.7
2
+1.42%
Sektor:
Basis:
Gewinnwährung:
Tagesspanne
Jahresspanne
Tagesänderung
+1.42%
Monatliche Änderung
-11.86%
6 month change
-38.49%
Jahresänderung
+6.32%
Vorheriger Schlusskurs
5.6
4
Open
5.7
2
Bid
Ask
Low
5.7
2
High
5.7
2
Volumen
58
Märkte
Aktien
Gesundheitswesen
VSTM
Open full chart
Financials
Overview
Finanzbericht
Statistics
Dividends
Quarterly
Annual
Income statement
Balance sheet
Cash flow
Value
2020
2021
2022
2023
2024
Total assets
154.35 M
108.66 M
95.05 M
149.72 M
101.54 M
Total liabilities
39.08 M
21.1 M
47.66 M
71.19 M
130.43 M
Total equity
115.27 M
87.56 M
47.39 M
57.37 M
28.89 M
Total liabilities & shareholders' equities
154.35 M
108.66 M
95.05 M
149.72 M
101.54 M
Total debt
—
—
—
—
—
Net debt
—
—
—
—
—
Verastem Inc
Verastem, Inc., doing business as Verastem Oncology, is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index.
Nachrichten
What Makes Verastem (VSTM) a New Buy Stock
Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results
Verastem: B.Riley bekräftigt "Buy"-Rating und Kursziel von 16 US-Dollar
B.Riley reiterates Buy rating on Verastem stock, maintains $16 target
Verastem meldet 17,5 Mio. US-Dollar Quartalsumsatz für Krebsmedikament
Verastem reports $17.5 million in Q4 revenue for cancer treatment
H.C. Wainwright startet Coverage für Verastem mit "Kaufen" und Kursziel 18 $/n
Verastem stock rating initiated at Buy by H.C. Wainwright with $18 target
Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data (NASDAQ:IMRX)
Revolution Medicines stock surges over 20% on potential AbbVie acquisition
What's Going On With Verastem Stock Friday? - Verastem (NASDAQ:VSTM)
Verastem stellt Studie ein – Mizuho bestätigt dennoch Outperform-Rating